FULC - Fulcrum Therapeutics Inc
IEX Last Trade
8.55
-0.190 -2.222%
Share volume: 493,652
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$8.74
-0.19
-2.17%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-08 | 2023-03-09 | 2023-05-15 | 2023-08-03 | 2023-11-07 | 2024-02-27 | 2024-05-13 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 247.805 M | 226.685 M | 321.120 M | 300.332 M | 278.879 M | 257.694 M | 232.588 M | 294.256 M | |
| Current Assets | 227.727 M | 207.519 M | 302.830 M | 282.947 M | 262.490 M | 242.199 M | 217.952 M | 280.286 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.135 M | 4.369 M | 4.891 M | 4.127 M | 4.819 M | 5.441 M | 4.638 M | 4.175 M | |
| Short Term Investments | 5.135 M | 4.369 M | 4.891 M | 4.127 M | 4.819 M | 5.441 M | 4.638 M | 4.175 M | |
| Total Receivables | 803.000 K | 229.000 K | 99.000 K | 656.000 K | 580.000 K | 537.000 K | 0.000 | 2.333 M | |
| Current Cash | 221.789 M | 202.921 M | 297.840 M | 278.164 M | 257.091 M | 236.221 M | 213.314 M | 273.778 M | |
| Total Non-current Assets | 20.078 M | 19.166 M | 18.290 M | 17.385 M | 16.389 M | 15.495 M | 14.636 M | 13.970 M | |
| Property Plant Equipment | 7.375 M | 6.906 M | 6.563 M | 6.161 M | 5.646 M | 5.216 M | 4.765 M | 4.408 M | |
| Other Assets | 11.611 M | 11.168 M | 10.635 M | 10.132 M | 9.651 M | 9.187 M | 8.670 M | 8.346 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 247.805 M | 226.685 M | 321.120 M | 300.332 M | 278.879 M | 257.694 M | 232.588 M | 294.256 M | |
| Total liabilities | 26.391 M | 27.743 M | 24.864 M | 24.904 M | 23.417 M | 22.501 M | 18.996 M | 20.466 M | |
| Total current liabilities | 14.699 M | 16.725 M | 14.407 M | 14.804 M | 14.075 M | 13.675 M | 10.694 M | 12.699 M | |
| Accounts Payable | 2.728 M | 3.638 M | 3.778 M | 3.909 M | 3.574 M | 2.757 M | 3.857 M | 3.584 M | |
| Other liabilities | 197.000 K | 197.000 K | 320.000 K | 447.000 K | 197.000 K | 197.000 K | 197.000 K | 197.000 K | |
| Current long term debt | 2.543 M | 2.602 M | 2.663 M | 2.507 M | 2.350 M | 2.192 M | 2.032 M | 2.082 M | |
| Long term debt | 11.495 M | 10.821 M | 10.137 M | 9.653 M | 9.145 M | 8.629 M | 8.105 M | 7.570 M | |
| Other liabilities | 197.000 K | 197.000 K | 320.000 K | 447.000 K | 197.000 K | 197.000 K | 197.000 K | 197.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 221.414 M | 198.942 M | 296.256 M | 275.428 M | 255.462 M | 235.193 M | 213.592 M | 273.790 M | |
| Common stock | 46.213 M | 52.217 M | 59.722 M | 61.794 M | 61.823 M | 61.901 M | 61.984 M | 62.205 M | |
| Retained earnings | -386.203 M | -412.338 M | -437.117 M | -460.900 M | -484.917 M | -509.673 M | -536.543 M | -481.134 M |